Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Pressure, Part I: Biotechs Feel the Chill

This article was originally published in Start Up

Executive Summary

Dismal conditions in the public capital markets can't help but affect biotech start-ups too. Venture capitalists are reassessing operating and exit strategies, and contemplating new business models.

You may also be interested in...



Terrorism's Impact on the Drug Industry

Terrorism has lowered investors' tolerance for risk. Investors aren't willing to accept as they have in the past the traditional uncertainties of biopharmaceutical investing. Instead, they are looking for companies that understand how to manage all risk, starting with technology and extending into partnering potential, the regulatory arena, and the marketplace. Beyond these visible dangers lies a subtle one: the societal risk posed by the drug industry's aggressive pricing strategies.

Super-Specialist CROs: Commercializing Pharma R&D Expertise

Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.

Spero Therapeutics: Remodeling Antibiotics

Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel